PubMed Health⌕ Search

Biomedical subjects

A F Ypma

Publications and source records attributed to A F Ypma.

17 recordsLinked to original sources
PubMed1996

Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.

OBJECTIVE: This meta-analysis of two European studies evaluated the efficacy and safety of modified-release tamsulosin 0.4 mg once daily compared with placebo in patients with benign prostatic enlargement, lower urinary tract symptoms and prostatic obstruction (symptomatic BPH). METHODS: Patients entered a 2-week placebo run-in period, followed by randomization to treatment with tamsulosin (382 patients) or placebo (193 patients) once daily for 12 weeks. RESULTS: Maximum urinary flow rate improved to a greater extent in the tamsulosin group (1.6 ml/s, 16%) than the placebo group (0.6 ml/s, 6%) (p = 0.002). Total Boyarsky symptom score also improved to a greater extent in the tamsulosin group (3.3 points, 35.1% reduction) than the placebo group (2.4 points, 25.5% reduction) (p = 0.002). Significantly more tamsulosin patients (66%) than placebo patients (49%) had a > or = 25% decrease in total symptom score at endpoint (p < 0.001). Twelve weeks of treatment with tamsulosin also produced significant improvements in average urinary flow rate (p = 0.005) and voiding or "obstructive" (p = 0.008) and storage or "irritative' (p = 0.017) symptom scores. The incidence of drug-related adverse events was comparable for the tamsulosin and placebo groups (13 and 12% respectively, p = 0.802). The same applies to the incidence of adverse events commonly attributed to alpha 1-adrenoceptor antagonists, such as dizziness, headache, postural hypotension, syncope, asthenia, somnolence and rhinitis. There were no clinically significant changes in blood pressure or pulse rate in tamsulosin patients compared with placebo patients both in hypertensive and normotensive BPH patients. CONCLUSION: Tamsulosin 0.4 mg once daily is safe, well-tolerated and improves both the symptoms and urinary flow rate in patients with benign prostatic obstruction (symptomatic BPH).

Administration, Oral↗
PubMed1995

Nephroptosis: a considerable cause of renovascular hypertension.

Four females were admitted with hypertension. Other causes of hypertension were excluded on clinical grounds. Digital substraction angiography performed in 3 patients revealed no stenosis of the renal arteries. The 99mTc-Mag3 renogram showed diminished perfusion and excretion on the affected side. Right-sided nephropexy was performed in all 4 cases via lumbotomy after which all 4 patients became normotensive. We conclude that nephroptosis is a considerable cause of renovascular hypertension and deserves particular attention in cases of possible renovascular hypertension when angiography shows no stenosis. We also conclude that renography is the preferred diagnostic method in the diagnosis of renovascular hypertension due to nephroptosis.

Adult↗
PubMed1994

A pelvic mass: bladder diverticulum with haemorrhage in Ehlers-Danlos patient.

We report on a case of haemorrhage in a large bladder diverticulum, impressing as a pelvic mass, in a patient with the Ehlers-Danlos syndrome. A review of the literature revealed 14 other cases of bladder diverticula and the Ehlers-Danlos Syndrome. Conservative treatment is first choice, unless complications occur.

Adult↗
PubMed1993

Evaluation of brachytherapy implants using the "natural" volume-dose histogram.

The "natural" volume-dose histogram as described by Anderson visualises graphically even small differences between source arrangements, making it a useful tool to compare planned and realised source configurations. In this study the histogram is applied to demonstrate that the introduction of an applicator in oral cavity implants or of iridium wire spacers used as templates in bladder implants improved the quality of the implants considerably, resulting in close agreement between the planned and the realised source configuration.

Brachytherapy↗
PubMed1992

Ultrasonically guided transperineal seed implantation of the prostate: modification of the technique and qualitative assessment of implants.

During the period 1988-1991, 23 patients with prostatic carcinoma were treated by transperineal iodine seed implantation guided by transrectal ultrasound. We introduce a refinement of the implantation technique using a rigid column of seeds and spacers. The uniformity parameter based on the peak width of the natural volume-dose histogram demonstrated quantitatively that this refinement resulted in a more accurate seed arrangement.

Brachytherapy↗
PubMed1989

Psoas abscess and giant fistula twenty-one years after nephrectomy.

Vague abdominal complaints and low back pain are common in modern medicine. We describe the case of a patient who presented these symptoms twenty-one years after a nephrectomy accompanied by persistent elevated erythrocyte sedimentation rate for unknown reason. CT and fistulography showed a psoas abscess and a giant fistula.

Abscess↗
PubMed1987

Dose determination in bladder and rectum during intracavitary irradiation of cervix carcinoma.

The radiation dosage in the base of the bladder and in the anterior wall of the rectum during intracavitary irradiation of cervix carcinoma can be determined easily by use of intracavitary transvesical and transrectal ultrasound and simultaneous radiography. In case of excessive doses to the organs at risk, the dose can be lowered by rearrangement of the vaginal gauze packing in the same sitting.

Brachytherapy↗
PubMedDate not supplied

[Brachytherapy for urinary bladder cancer].

OBJECTIVE: To present the results achieved by brachytherapy in the treatment of bladder cancer and to review the literature on this subject. METHODS: 120 patients with bladder cancer were treated with brachytherapy at two Dutch Centres. Selection criteria were good general condition allowing anesthesia, good bladder function (capacity of 300 ml), solitary tumor maximum 5 cm diameter, T1G3, T2, T3a. Before the implant an extensive transurethral resection was performed. The urologist carried out a cystostomy and the radiation oncologist did the implant using iridium-192 wires. The administered tumor dose was 60 Gy at a dose rate of 60-90 cGy/hour. RESULTS: The 5-year overall survival and disease-free survival was 67% and 73%, respectively. By stage, the 5-year disease-free survival was 100% in T1, 80% in T2 and 67% in T3. Local failure was observed in 15 patients (13%). Six of these relapses were salvaged by cystectomy. Ten patients had a superficial tumor Ta-T1 in bladder sites other than the original tumor site. Acute and late complications were unusual. The results compare quite well with those of other series published in the literature. CONCLUSION: Brachytherapy achieves excellent results in selected patients with solitary bladder cancer maintaining a fully functional bladder. Acute and late complications of this treatment modality are relatively infrequent.

Adult↗